Jason M. Broderick

Articles

IL-15 superagonist N-803 shows strong clinical activity in papillary NMIBC

October 20, 2021

Data from the phase 2/3 QUILT-3.032 trial showed that adding N-803 to BCG met the primary end point of disease-free survival in patients with BCG-unresponsive, high-grade non–muscle-invasive bladder cancer and papillary disease.